One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback